Posts
Amitriptyline is an antidepressant and nerve pain medication used
in the treatment of depression, nocturnal enuresis, migraine, and chronic neuropathic
pain. High prevalence of migraine is expected to propel growth of the amitriptyline
market. For instance, according to the study, ‘Prevalence, burden, and clinical
management of migraine in China, Japan, and South Korea: a comprehensive review
of the literature’, published in December 2019, in BMC’s The Journal of
Headache and Pain, the 1-year prevalence of migraine among adults ranged from
6.0% to 14.3%.
Emergence of Covid-19 is expected to offer lucrative growth
opportunities for players in the amitriptyline market. The outbreak has led to
significant increase in the number of depression cases. For instance, according
to a study published in September 2020, in JAMA Network Open, COVID-19 has
tripled the rate of depression in US adults in all demographic
groups—especially in those with financial worries. Moreover, use of amitriptyline
in combination with other drugs for the treatment of epidermolysis bullosa
pruriginosa, a very rare pattern of dystrophic EB caused by type VII collagen
gene mutation, is also expected to aid in growth of the market. For instance,
according to the report “Epidermolysis Bullosa Pruriginosa successfully treated
with concomitant topical and systemic agents,” published in July 2020, in the
Australasian Journal of Dermatology, the combination of the oral antidepressant
mirtazapine with a topical gel containing ketamine and amitriptyline
successfully treated excessive itching in a man with epidermolysis bullosa
pruriginosa.
R&D in amitriptyline is expected to aid in growth of the amitriptyline
market. For instance, according to the study, ‘Therapeutic Dose of
Amitriptyline for Older Patients with Burning Mouth Syndrome’, published in
Dovepress in December 2019, therapeutic dose of amitriptyline may be lower for
older burning mouth syndromepatients than for younger patients. Similarly, in
August 2020, researchers from the Emory University School of Medicine, reported
that amitriptyline may have the ability to mimic the brain’s own growth
factors.
Competitive Analysis
Major players operating in the amitriptyline market include, Accord
Healthcare Inc., Mylan Pharmaceuticals Inc., Sandoz Inc., Sun Pharmaceutical
Industries Inc., Vintage Pharmaceuticals Inc., Zydus Pharmaceuticals USA Inc.,
Watson laboratories Inc., and Torrent Pharmaceuticals Ltd.
June 2020: AlgoTherapeutix, an innovator in complex pain therapy, announced
that the U.S. Food and Drug Administration (FDA) has granted ATX01 (proprietary
topical amitriptyline) Orphan Drug Designation for the treatment of erythromelalgia,
a condition characterized by episodes of pain, redness, and swelling in various
parts of the body, particularly the hands and feet.
No comments:
Post a Comment